RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control
2014-01-01 Simonelli, M; Denlinger, Cs; Goff, Lw; Noberasco, C; Kim, Ty; Thomas, Mb; De Braud, Fg; Zucali, Pa; Santoro, A; English, Pa; Gallo-Stampino, C; Wang, Ej; Carpentieri, M; Williams, Ja
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors
2011-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Lorenzi, E; Rimassa, L; Balzarini, L; Quagliuolo, V; Lambiase, A; Bordignon, C; Santoro, A
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS
2010-01-01 Zucali, Pa; Santoro, A; Simonelli, M; De Vincenzo, F; Lorenzi, E; Rimassa, L; Balzarini, L; Quagliuolo, V; Lambiase, A; Bordignon, C
Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors
2012-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Lorenzi, E; Perrino, M; Bertossi, M; Balzarini, L; Bonifacio, C; Lambiase, A; Bordignon, C; Santoro, A
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors
2010-01-01 Simonelli, M; Santoro, A; Zucali, Pa; Rimassa, L; De Vincenzo, F; Pressiani, T; Tronconi, Mc; Carnaghi, C; Lambiase, A; Bordignon, C
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC)
2013-01-01 Simonelli, M; Zucali, Pa; Thomas, Mb; Brisendine, A; Berlin, J; Noberasco, C; Denlinger, Cs; Kim, Ty; Santoro, A; Gallo-Stampino, C; Carpentieri, M; Wang, Ej; Williams, Ja; De Braud, Fg
Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma
2015-01-01 Zucali, Pa; Simonelli, M; De Vincenzo, F; Fatuzzo, G; Bertossi, M; Perrino, M; Miggiano, C; Giordano, L; Bonifacio, C; Sposta, Fm; Santoro, A
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors
2011-01-01 Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mc; Personeni, N; Masci, G; Zuradelli, M; Perrino, M; Bertossi, M; Giordano, L; Santoro, A
Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours
2011-01-01 Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mg; Zuradelli, M; Giordano, L; Santoro, A
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
2011-01-01 Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mc; Personeni, N; Masci, G; Zuradelli, M; Giordano, L; Santoro, A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control | 1-gen-2014 | Simonelli, M; Denlinger, Cs; Goff, Lw; Noberasco, C; Kim, Ty; Thomas, Mb; De Braud, Fg; Zucali, Pa; Santoro, A; English, Pa; Gallo-Stampino, C; Wang, Ej; Carpentieri, M; Williams, Ja | |
| Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors | 1-gen-2011 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Lorenzi, E; Rimassa, L; Balzarini, L; Quagliuolo, V; Lambiase, A; Bordignon, C; Santoro, A | |
| PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS | 1-gen-2010 | Zucali, Pa; Santoro, A; Simonelli, M; De Vincenzo, F; Lorenzi, E; Rimassa, L; Balzarini, L; Quagliuolo, V; Lambiase, A; Bordignon, C | |
| Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors | 1-gen-2012 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Lorenzi, E; Perrino, M; Bertossi, M; Balzarini, L; Bonifacio, C; Lambiase, A; Bordignon, C; Santoro, A | |
| Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors | 1-gen-2010 | Simonelli, M; Santoro, A; Zucali, Pa; Rimassa, L; De Vincenzo, F; Pressiani, T; Tronconi, Mc; Carnaghi, C; Lambiase, A; Bordignon, C | |
| Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC) | 1-gen-2013 | Simonelli, M; Zucali, Pa; Thomas, Mb; Brisendine, A; Berlin, J; Noberasco, C; Denlinger, Cs; Kim, Ty; Santoro, A; Gallo-Stampino, C; Carpentieri, M; Wang, Ej; Williams, Ja; De Braud, Fg | |
| Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma | 1-gen-2015 | Zucali, Pa; Simonelli, M; De Vincenzo, F; Fatuzzo, G; Bertossi, M; Perrino, M; Miggiano, C; Giordano, L; Bonifacio, C; Sposta, Fm; Santoro, A | |
| Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors | 1-gen-2011 | Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mc; Personeni, N; Masci, G; Zuradelli, M; Perrino, M; Bertossi, M; Giordano, L; Santoro, A | |
| Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours | 1-gen-2011 | Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mg; Zuradelli, M; Giordano, L; Santoro, A | |
| Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors | 1-gen-2011 | Simonelli, M; Zucali, Pa; De Sanctis, R; Lorenzi, E; De Vincenzo, F; Rimassa, L; Tronconi, Mc; Personeni, N; Masci, G; Zuradelli, M; Giordano, L; Santoro, A |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 4 Contributo in Atti di Convegno ... 35
- 4 Contributo in Atti di Convegno ... 34
- 4 Contributo in Atti di Convegno ... 1
Data di pubblicazione
- 2010 - 2017 29
- 2004 - 2009 6
Rivista
- JOURNAL OF CLINICAL ONCOLOGY 15
- ANNALS OF ONCOLOGY 9
- EUROPEAN JOURNAL OF CANCER 3
- JOURNAL OF THORACIC ONCOLOGY 2
- NEURO-ONCOLOGY 2
- EUROPEAN ASSOCIATION OF NEUROONCO... 1
- EUROPEAN JOURNAL OF CANCER. SUPPL... 1
- EUROPEAN JOURNAL OF NUCLEAR MEDIC... 1
- INTERNATIONAL JOURNAL OF RADIATIO... 1
Accesso al fulltext
- no fulltext 35